COMPARISON OF MOEXIPRIL, A NEW ACE-INHIBITOR, TO VERAPAMIL-SR AS ADD-ON THERAPY TO LOW-DOSE HYDROCHLOROTHIAZIDE IN HYPERTENSIVE PATIENTS

被引：19
作者：
CHRYSANT, SG
FOX, AAL
STIMPEL, M
机构：
[1] Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma
[2] Department of Clinical Research, Schwarz Pharma, Monheim
来源：
AMERICAN JOURNAL OF HYPERTENSION | 1995年 / 8卷 / 04期
关键词：
MOEXIPRIL; VERAPAMIL-SR; HYDROCHLOROTHIAZIDE; HYPERTENSION;
D O I：
10.1016/0895-7061(94)00025-7
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
The antihypertensive effects of moexipril, a new angiotensin converting enzyme inhibitor, and verapamil-SR as add-on therapy to hydrochlorothiazide (HCTZ) were investigated in patients with moderate to severe (stages II and III) essential hypertension. Of 147 patients treated for 4 weeks with 25 mg/day HCTZ, 108 whose sitting diastolic blood pressure (SDBP) was 100 to 114 mm Hg inclusive were randomized to 7.5 mg/day moexipril (56 patients) and 180 mg/day verapamil-SR (52 patients) in addition to 25 mg/day HCTZ. If after 4 weeks of treatment the SDBP was greater than or equal to 90 mm Hg, the dose of moexipril was increased to 15 mg/day and that of verapamil-SR increased to 240 mg/day; the patients were followed for an additional 8 weeks. Blood chemistries, plasma renin activity, and plasma aldosterone were done during the study. Both moexipril and verapamil-SR were safe and well tolerated and decreased the sitting and standing blood pressure similarly (P < .001). This study demonstrated that the addition of moexipril and verapamil-SR to low dose HCTZ is effective for the treatment of moderate to severe hypertension.
引用
收藏
页码：418 / 421
页数：4
相关论文
共 15 条
  • [1] Investigators Brochure, February 3, (1992)
  • [2] Grass GM, Moorehead WT, Evidence for site-specific absorption of a novel ACE inhibitor, Pharmaceut Res, 6, pp. 759-765, (1989)
  • [3] Rosenkranz RP, Hayashi CM, Lakatos I, McClelland DL, Diuretic effects of an ACE inhibitor, RS-10085, and hydrochlorothiazide in the spontaneously hypertensive rat, Proc West Pharmacol Soc, 32, pp. 221-225, (1989)
  • [4] Chrysant SG, Antihypertensive effectiveness of low dose lirinopril/hydrochlorothiazide combination: a large multicenter study, Arch Intern Med, 154, pp. 737-743, (1994)
  • [5] Chrysant SG, Experience with terazosin administered in combination with other antihypertensive agents, Am J Med, 80, pp. 55-61, (1986)
  • [6] Chrysant SG, Chappel C, Farnham DJ, Et al., Antihypertensive and metabolic effects of single and combined atenolol regimens, J Clin Pharmacol, 32, pp. 61-65, (1992)
  • [7] Kochar M, Bolek G, Kalbfleisch J, Olzinski P, A 52-week comparison of lisinopril, hydrochlorothiazide, and their combination in hypertension, J Clin Pharmacol, 27, pp. 373-377, (1987)
  • [8] Weinberger MH, Angiotensin converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects, Journal of Cardiovascular Pharmacology, 13, pp. 1-4, (1989)
  • [9] Holland OB, Kuhnert L, Campbell WB, Anderson RJ, Synergistic effect of Captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients, Hypertension, 5, pp. 235-239, (1983)
  • [10] Massie B, McCarthy EP, Ramanathan KB, Et al., Diltiazem and propranolol in mild to moderate essential hypertension monotherapy or with hydrochlorothiazide, Ann Intern Med, 107, pp. 150-157, (1987)
12